International registry on splanchnic vein thrombosis: description of the study population

Details

Serval ID
serval:BIB_54060B832863
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Title
International registry on splanchnic vein thrombosis: description of the study population
Title of the conference
23th Congress of the International Society on Thrombosis and Haemostasis, 57th Annual SSC Meeting
Author(s)
Ageno W., Schulman S., Riva N., Bang S.M., Sartori M.T., Beyer J., Barillari G., Grandone E., Malato A., Santoro R., Duce R., Martinelli I., Poli D., Alatri A., Verhamme P., Kamphuisen P.W., Oh D., Becattini C., Bucherini E., Dentali F.
Working group(s)
Study Investigators IRSVT
Address
Kyoto, Japan, July 23-28, 2011
ISBN
1538-7836
ISSN-L
1538-7933
Publication state
Published
Issued date
2011
Volume
9
Series
Journal of Thrombosis and Haemostasis
Pages
304
Language
english
Abstract
Background: Splanchnic vein thrombosis (SVT) is an uncommon, butpotentially life-threatening disease. Aim of this ISTH based registryis to improve the knowledge on SVT by studying a large, international,unselected population.Methods: Consecutive patients with objectively diagnosed SVT areeligible for the registry. Information on clinical presentations, diagnosticapproaches, risk factors, therapeutic approaches, and recurrencesof SVT, bleedings and deaths at a 2 year follow up are enteredon a website database (www.svt.altervista.org). We planned a samplesize of 500 patients, including all sites of thrombosis.Results: As of December 31st, 2010, 429 patients with SVT (85.8%of the planned sample) have been enrolled at 25 centres from sevencountries. The mean age is 52.6 years (range 16-85 years); 62.2% aremales, 67.8% are Caucasians, and 31.2% Asians. SVT occurred inmultiple vein segments in 36.4% of patients, 40.5% of patients hadisolated portal vein thrombosis, 11.9% of patients had mesentericvein thrombosis, 7.5% had supra-hepatic vein thrombosis, and 3.6%had splenic vein thrombosis. Abdominal pain was the most commonsymptom occurring in 56.6% of the patients; 9.5% of patients hadgastrointestinal bleeding at the time of diagnosis; 25.4% of patientswith SVT were asymptomatic. Mean time between onset of symptomsand diagnosis was 7.4 days. Objective diagnosis was obtained withabdominal CT in 79.9% of patients. Most common risk factors atthe time of diagnosis included cancer (24.1%), cirrhosis (23.1%), andhematological disorders (15.4%); in 15.9% of patients SVT was idiopathic.Most patients were treated with anticoagulant drugs: 30.8%with parenteral drugs only, 56.9% with parenteral drugs followed byvitamin K antagonists.Conclusions: SVT is a major challenge for experts in thrombosis andhemostasis. Large collaborative studies are necessary to improve theunderstanding and the management of this heterogeneous disease.
Create date
16/02/2012 15:24
Last modification date
03/06/2020 5:26
Usage data